Personalized approach to the treatment of patients with arterial hypertension: focus on imidazoline receptor agonists. Opinion on the problem

Hypertension (HTN) remains one of the most pressing problems of modern healthcare. Morbidity and mortality associated with HTN continue to increase, despite a wide range of available antihypertensive agents and regular updates of related clinical guidelines. In October 2024, an annual forum was held to discuss the optimization of approaches to the treatment of HTN. During the discussion, special attention was paid to personalized therapy of patients, which should be based on modern concepts of the disease pathogenesis and individual risk factors. In addition, the validity of prescribing imidazoline receptor agonists, which are additional agents that lower blood pressure, in certain clinical situations was discussed, along with the main five classes of antihypertensive drugs. In routine practice, it is recommended to consider the use of centrally acting drugs, in particular moxonidine, to control hypertension as part of combination therapy. A central sympathetic inhibition with moxonidine therapy ensures control of blood pressure and has pleiotropic effects, among which the most important is an increase in tissue sensitivity to insulin. This is especially important for the treatment of hypertension in patients with obesity, metabolic syndrome, prediabetes, type 2 diabetes, in patients with various metabolic disorders (hyperglycemia, dyslipidemia, hyperuricemia) and in women in the peri- and postmenopausal period.

1. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.

2. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178.

3. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) . doi:10.15829/1560-4071-2024-6117.

4. Kario K, Okura A, Hoshide S, et al. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024; 47(5):1099-102. doi:10.1038/s41440-024-01622-w.

5. Erina AM, Rotar OP, Solntsev VN, et al. Epidemiology of Arterial Hypertension in Russian Federation — Importance of Choice of Criteria of Diagnosis. Kardiologiia. 2019;59(6):5-11. (In Russ.). doi:10.18087/cardio.2019.6.2595.

6. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.). doi:10.15829/1728-8800-2023-3785.

7. Grassi G, Drager LF. Sympathetic overactivity, hypertension and cardiovascular disease: state of the art. Curr Med Res Opin. 2024;40(Sup1):5-13. doi:10.1080/03007995.2024.2305248.

8. Konradi AO. Interrelation between sympathetic and renin-angiotensin systems: Role in arterial hypertension. Arterial’naya Gipertenziya (Arterial Hypertension). 2012;18(6):577-83. (In Russ.). doi:10.18705/1607-419X-2012-18-6-577-583.

9. Chaturvedi A, Zhu A, Gadela NV, et al. Social Determinants of Health and Disparities in Hypertension and Cardiovascular Diseases. Hypertension. 2024;81(3):387-99. doi:10.1161/HYPERTENSIONAHA.123.21354.

10. Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med. 2018;215(1):21-33. doi:10.1084/jem.20171773.

11. Harrison DG, Patrick DM. Immune Mechanisms in Hypertension. Hypertension. 2024;81(8):1659-74. doi:10.1161/HYPERTENSIONAHA.124.21355.

12. Ge Y, Wang J, Wu L, et al. Gut microbiota: a potential new regulator of hypertension. Front Cardiovasc Med. 2024;11. doi:10.3389/fcvm.2024.1333005.

13. Cui X, Zhang T, Xie T, et al. Research Progress on the Correlation Between Hypertension and Gut Microbiota. J Multidiscip Healthc. 2024;17:2371-87. doi:10.2147/JMDH.S463880.

14. Kario K, Tomitani N, Wang TD, et al. Home blood pressure-centered approach — from digital health to medical practice: HOPE Asia Network consensus statement 2023. Hypertens Res. 2023;46(12):2561-74. doi:10.1038/s41440-023-01397-6.

15. Baranova EI, Katsap AA, Kolesnik OS, et al. Hypertension in peri- and postmenopausal women — pathophysiological mechanisms and approaches to treatment. Russian Journal of Cardiology. 2023;28(5):5439. (In Russ.). doi:10.15829/1560-4071-2023-5439.

16. Li S, Tan I, Atkins E, et al. The Pathophysiology, Prognosis and Treatment of Hypertension in Females from Pregnancy to Post-menopause: A Review. Curr Heart Fail Rep. 2024;21(4):322-36. doi:10.1007/s11897-024-00672-y.

17. Bager JE, Manhem K, Andersson T, et al. Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care. J Hum Hypertens. 2023; 37(8):662-70. doi:10.1038/s41371-023-00801-5.

18. Handler J. Managing Erectile Dysfunction in Hypertensive Patients. J Clin Hypertens. 2011;13(6):450-4. doi:10.1111/j.1751-7176.2011.00465.x.

19. Kajiwara A, Saruwatari J, Kita A, et al. Younger Females Are at Greater Risk of Vasodilation-Related Adverse Symptoms Caused by Dihydropyridine Calcium Channel Blockers: Results of a Study of 11,918 Japanese Patients. Clin Drug Invest. 2014;34(6):431-5. doi:10.1007/s40261-014-0191-4.

20. Stimpel M, Koch B, Oparil S. Antihypertensive Treatment in Postmenopausal Women: Results from a Prospective, Randomized, Double-Blind, Controlled Study Comparing an ACE Inhibitor (Moexipril) with a Diuretic (Hydrochlorothiazide). Cardiology. 1998;89(4):271-6. doi:10.1159/000006799.

21. Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.

22. Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin. 2004;20(3):359-67. doi:10.1185/030079904125002991.

23. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004; 18(9):669-75. doi:10.1038/sj.jhh.1001676.

24. Skibitskiy VV, Gutova SR, Fendrikova AV, et al. Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes. Kardiologiia. 2020;60(4):10-7. (In Russ.) . doi:10.18087/cardio.2020.4.n1112.

25. Chubenko ЕА, Belyaeva ОD, Bazhenova ЕА, et al. Pleiotropic effects of moxonidine. Arterial’naya Gipertenziya (Arterial Hypertension). 2010;16(4):351-5. (In Russ.). doi:10.18705/1607-419X-2010-16-4-351-355.

26. Haczynski J, Flasinski J, Przewlocka-Kosmala M, et al. Effect of moxonidine on left ventricular hypertrophy in hypertensive patients. J Clin Basic Cardiol. 2001;4(1):61-5.

27. Littlewood KJ, Greiner W, Baum D, et al. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrol. 2007;8(1):9. doi:10.1186/1471-2369-8-9.

28. Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine Effect on Microalbuminuria, Thrombomodulin, and Plasminogen Activator Inhibitor-1 Levels in Patients with Essential Hypertension. Cardiovasc Drugs Ther. 1998;12(5):463-7. doi:10.1023/A:1007702132210.

29. Martynov AI, Ostroumova OD, Mamaev VI, et al. Possibilities of moxonidine (physiotens) in the treatment of arterial hypertension in elderly patients. Clinical gerontology. 2005;11:77-83. (In Russ.).

30. Dudinskaya EN, Tkacheva ON, Bazaeva EV, et al. New possibilities of using moxonidin for blood pressure control in female patients with osteopenia. Kardiologiia. 2018;58(7S):36-45. (In Russ.). doi:10.18087/cardio.2508.

31. Chazova IE, Zhernakova YuV, Blinova NV, et al. Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). Eurasian heart journal. 2022;(3):6-56. (In Russ.). doi:10.38109/2225-1685-2022-3-6-56.

32. Shlyakhto EV, Konradi AO, Zvartau NE, et al. Influence on the autonomic cardiovascular system regulation in the treatment of hypertension, arrhythmias and heart failure. Russian Journal of Cardiology. 2022;27(9):5195. (In Russ.). doi:10.15829/1560-4071-2022-5195.

33. Schlaich MP, Tsioufis K, Taddei S, et al. Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement. J Hypertens. 2024;42(12):2025-40. doi:10.1097/HJH.0000000000003769.

34. Polyakova EA, Konradi AO, Baranova EI, et al. Hypertension in periand postmenopausal women: mechanisms, management, observation. Russian Journal of Cardiology. 2024;29(1):5729. (In Russ.) . doi:10.15829/1560-4071-2024-5729.

35. Polyakova EA, Konradi AO, Baranova EI, et al. Current approaches to the treatment of hypertensive patients in view of modern guidelines. Cardiovascular Therapy and Prevention. 2024;23(8):4140. (In Russ.). doi:10.15829/1728-8800-2024-4140.

36. Zhernakova YuV. Modern ideas about the consequences of sympathoadrenal hyperactivation in hypertensive patients with metabolic disorders: modulation possibilities. Russian Journal of Cardiology. 2023;28(12):5681. (In Russ.). doi:10.15829/1560-4071-2023-5681.

37. Grassi G, Biffi A, Seravalle G, et al. Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. J Hypertens. 2021;39(3):408-16. doi:10.1097/HJH.0000000000002661.

38. Hall JE, do Carmo JM, da Silva AA, et al. Obesity-Induced Hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. doi:10.1161/CIRCRESAHA.116.305697.

39. Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol. 2021;20(1):170. doi:10.1186/s12933-021-01356-w.

40. Rump L. The Role of Sympathetic Nervous Activity in Chronic Renal Failure. J Clin Basic Cardiol. 2001;4(3):179-82.

41. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35. doi:10.1161/CIR.0000000000001184.

42. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21(9):1709-17. doi:10.1097/00004872-200309000-00021.

43. Rotar OP, Ilyanova IN, Boyarinova MA, et al. 2023 All-Russian screening for hypertension: results. Russian Journal of Cardiology. 2024;29(5):5931. (In Russ.). doi:10.15829/1560-4071-2024-5931.

44. Terentes-Printzios D, Ioakeimidis N, Rokkas K, et al. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat Rev Cardiol. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6.

45. Konradi AO, Zvartau NE, Chazova IE, et al. Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. Terapevticheskii arkhiv. 2021; 93(4):440-8. (In Russ.). doi:10.26442/00403660.2021.04.200818.

46. Ruksin VV, Grishin OV, Syamtomov AS. Hypertension emergencies. Brands or generics? Emergency medical care. 2015; 16(3):16-20. (In Russ.). doi:10.24884/2072-6716-2015-16-3-16-20.

47. Ruksin VV, Grishin OV, Onuchin MV. Comparison of the effectiveness of preparations containing moxonidine during emergency antihypertensive therapy. Systemic Hypertension. 2015; 12(2):8-12. (In Russ.)

48. Skibitskiy VV, Fendrikova AV, Skibitskiy AV, et al. Original Moxonidine and Generics: Where is the Edge of Difference? Kardiologiia. 2024;64(8):24-31. (In Russ.). doi:10.18087/cardio.2024.8.n2731.